112 related articles for article (PubMed ID: 15499696)
1. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib for advanced or metastatic non-small cell lung cancer.
Perras C
Issues Emerg Health Technol; 2004 Apr; (55):1-4. PubMed ID: 15085875
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage.
Prescrire Int; 2006 Jun; 15(83):86-9. PubMed ID: 16764093
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Prescrire Int; 2009 Aug; 18(102):145-7. PubMed ID: 19739343
[TBL] [Abstract][Full Text] [Related]
5. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
Wang F; Wang LD; Li B; Sheng ZX
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):396-401. PubMed ID: 22019482
[TBL] [Abstract][Full Text] [Related]
8. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; Pazdur R
Oncologist; 2003; 8(4):303-6. PubMed ID: 12897327
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib therapy for advanced non-small-cell lung cancer.
Liu CY; Seen S
Ann Pharmacother; 2003 Nov; 37(11):1644-53. PubMed ID: 14565788
[TBL] [Abstract][Full Text] [Related]
10. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Wolf M; Swaisland H; Averbuch S
Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
[TBL] [Abstract][Full Text] [Related]
11. The role of gefitinib in lung cancer treatment.
Giaccone G
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4233s-4237s. PubMed ID: 15217964
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.
van Zandwijk N
Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S9-14. PubMed ID: 14661047
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Cersosimo RJ
Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
[TBL] [Abstract][Full Text] [Related]
15. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Forsythe B; Faulkner K
Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Padda SK; Chhatwani L; Zhou L; Jacobs CD; Lopez-Anaya A; Wakelee HA
Anticancer Drugs; 2013 Aug; 24(7):731-5. PubMed ID: 23552470
[TBL] [Abstract][Full Text] [Related]
17. Acute gefitinib-induced pneumonitis.
Ohyanagi F; Ando Y; Nagashima F; Narabayashi M; Sasaki Y
Int J Clin Oncol; 2004 Oct; 9(5):406-9. PubMed ID: 15549594
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib.
Culy CR; Faulds D
Drugs; 2002; 62(15):2237-48; discussion 2249-50. PubMed ID: 12381224
[TBL] [Abstract][Full Text] [Related]
19. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Togashi Y; Masago K; Fujita S; Hatachi Y; Fukuhara A; Nagai H; Sakamori Y; Kim YH; Mio T; Mishima M
Lung Cancer; 2011 Oct; 74(1):98-102. PubMed ID: 21377230
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib (Iressa) trials in non-small cell lung cancer.
Johnson DH
Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
